全身磁共振成像采用MET-RADS-P标准评估转移性激素初治及去势抵抗性前列腺癌对强化雄激素剥夺治疗反应的价值
研究前瞻性对37例转移性激素初治前列腺癌(mHNPC)和51例去势抵抗性前列腺癌(mCRPC)患者在雄激素剥夺治疗联合雄激素受体通路抑制剂(ARPI)6-12月前后行全身磁共振成像(wbMRI)。按MET-RADS-P标准评估影像反应,PSA反应定义为mHNPC中PSA≤0.2 ng/ml、mCRPC中较治疗前下降≥50%。mHNPC中PSA与wbMRI反应一致性为中等(κ=0.30),mCRPC中为无至轻微(κ=0.15);mHNPC中wbMRI进展与死亡风险显著升高相关(HR 8.59;p=0.002)。
要点
- mHNPC中PSA与wbMRI反应一致性中等(κ=0.30),mCRPC中一致性无至轻微(κ=0.15)。
- mHNPC中wbMRI进展与死亡风险显著升高相关(HR 8.59;p=0.002)。
- mCRPC中PSA反应者三分之二在wbMRI上显示进展,PSA或wbMRI进展未改变后续治疗可能性或死亡风险。
核心结论
- 在mHNPC中,wbMRI进展与需要后续治疗的风险更高及总生存期更短相关。
研究设计与样本
- 前瞻性研究,纳入37例mHNPC和51例mCRPC患者,在雄激素剥夺治疗联合ARPI 6-12月前后行wbMRI。
- 影像反应按MET-RADS-P标准定义,PSA反应在mHNPC中定义为PSA≤0.2 ng/ml、在mCRPC中定义为较治疗前下降≥50%。
- 采用Cohen's κ评估PSA与wbMRI反应一致性,采用Cox回归分析至后续治疗时间与总生存期的关联。
主要发现
- PSA与wbMRI反应一致性在mHNPC中为中等(κ=0.30),在mCRPC中为无至轻微(κ=0.15)。
- mHNPC中PSA或wbMRI反应者接受后续治疗的可能性更低;wbMRI进展与死亡风险显著升高相关(HR 8.59;p=0.002)。
- mCRPC中PSA反应者三分之二在wbMRI上显示进展;PSA或wbMRI进展均未改变启动后续治疗的可能性或死亡风险。
临床怎么用
- 作者指出,将PSA与全身MRI联合可能更准确地反映晚期前列腺癌的治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: We assessed the agreement between prostate-specific antigen (PSA) and imaging responses using whole-body magnetic resonance imaging (wbMRI). Our aim was to explore the potential prognostic value of PSA and wbMRI responses in metastatic hormone-naïve prostate cancer (mHNPC) and castration-resistant PC (mCRPC). METHODS: wbMRI was prospectively performed in 37 patients with mHNPC and 51 with mCRPC before and after 6-12 mo of androgen deprivation therapy and an androgen receptor pathway inhibitor (ARPI). Imaging responses were defined according to the Metastasis Reporting and Data System for PC (MET-RADS-P) criteria. A PSA response was defined as PSA ≤0.2 ng/ml in mHNPC and a ≥50% decrease from the pretreatment level in mCRPC. Agreement between PSA and wbMRI responses was assessed using Cohen's κ. The association between time to subsequent treatment and overall survival (OS) was analyzed using Cox regression analysis. KEY FINDINGS AND LIMITATIONS: Agreement between PSA and wbMRI responses was fair in mHNPC (κ = 0.30) but none to slight in mCRPC (κ = 0.15). In mHNPC, patients with a PSA or wbMRI response were less likely to receive subsequent treatments; wbMRI progression was associated with a significantly higher risk of death (hazard ratio 8.59; p = 0.002). In mCRPC, two-thirds of patients with a PSA response showed progression on wbMRI; neither PSA nor wbMRI progression changed the likelihood of starting a subsequent treatment or the risk of death. CONCLUSIONS AND CLINICAL IMPLICATIONS: In mHNPC, wbMRI progression was associated with a higher risk of needing subsequent treatment and shorter OS. PATIENT SUMMARY: We evaluated the agreement between routine PSA (prostate-specific antigen) test results and whole-body MRI (magnetic resonance imaging) scans for assessing the response of metastatic prostate cancer to treatment. There was disagreement between the PSA and MRI results, mainly for patients with cancer that was resistant to hormone-based treatment. Combining PSA with whole-body MRI might provide a more accurate picture of the response of advanced prostate cancer to treatment.
引用
- Van Damme J, Tombal B, Michoux N, et al. Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39505670. doi:10.1016/j.euo.2024.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。